Revised SPC: Zejula (niraparib) 100 mg hard capsules

SPC has been updated to warn that there have been reports of posterior reversible encephalopathy syndrome in patients receiving Zejula, a diagnosis of which requires confirmation by brain imaging. Hypertensive crisis has also been added as a rare adverse reaction.


electronic Medicines compendium